Normal tissue protection in cancer therapy--progress and prospects

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• Normal tissue tolerance is critical for effective cancer treatment, often limiting radiation and chemotherapy doses.
• Chemical protectors have been investigated to mitigate radiation and drug-induced toxicity in normal tissues.
• WR-2721, an aminothiol, is a notable chemical protector but faces challenges due to systemic toxicity in clinical settings.

Purpose of the Study:

• To review advancements in chemical protectors for enhancing normal tissue tolerance in cancer therapy.
• To analyze the efficacy and toxicity profiles of various protective agents, including WR-2721 and newer compounds.
• To explore strategies for improving WR-2721's therapeutic index through combination therapies.

Main Methods:

• Literature review of major reports on chemical protectors published in the last ten years.
• Analysis of studies investigating radiation and chemotherapy protective agents.
• Evaluation of clinical trial data and preclinical research on chemical radioprotectors and chemoprotectors.

Main Results:

• WR-2721, despite its effectiveness, exhibits systemic toxicity limiting its routine use in radiotherapy.
• The 1980s saw the emergence of non-thiol protectors, including biological response modifiers and antioxidants.
• Combining WR-2721 with less potent protective chemicals can improve its protective effects and reduce toxicity.

Conclusions:

• Chemical protectors play a vital role in improving cancer treatment outcomes by preserving normal tissues.
• Newer non-thiol protectors and combination strategies offer promising alternatives to overcome the limitations of existing agents like WR-2721.
• Continued research into chemical protection is essential for advancing safe and effective cancer therapies.